Division of Rheumatology

University of Colorado Anschutz Medical Campus

Myositis Studies

The Division of Rheumatology strives to understand more about myositis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.

Study Name/IRB#/PI

Brief Description

Basic Eligibility Criteria

Contact

CAR-T study in SLE, IIM and SSc

24-0289

Melissa Griffith, MD

A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, idiopathic Inflammatory Myopathy or Systemic Sclerosis

Adult women or men (age 18 and above) with confirmed, active SLE, IIM, SSc

Fulfilling the 2017 EULAR/ACR classification criteria for probable(score of 5.5 without biopsies; 6.7 with biopsies) or definite IIM (score of ≥ 7.5 without muscle biopsy and ≥ 8.7 with muscle biopsy)
Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.
Severe muscle AND/OR skin involvement.
Inadequate response to glucocorticoids and at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, leflunomide, IVIG, and rituximab.
Other systemic autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded.

Chong Pedrick

303-724-7518

Chong.Pedrick@cuanschutz.edu

Najeeb Arishi

303-724-7512

Najeeb.Arishi@cuanschutz.edu

Mario Farag

303-724-6438

Mario.Farag@cuanschutz.edu